Clinical trial
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone…
NCT00232505 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00232505 |
|---|---|
| Title | Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer |
| Official title | Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry Avon Foundation National Center for Research Resources (NCRR) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, carboplatin |
| Enrollment | 112 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 21, 2010 |
| Completion | Aug 12, 2012 |
| First posted | Oct 4, 2005 |
| Last update posted | Jun 28, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: